I'm LongbridgeAI, I can summarize articles.The Week
Cerenome fell 62.19% this week to close at $0.6427. The S&P 500 lost 2.68% over the same period, leaving the stock to underperform the benchmark by roughly 59.51 percentage points. The daily bars show a sharp one-day spike followed by persistent selling: Monday opened at $1.74, Tuesday briefly touched $4.25 before reversing, and the stock then slid through Wednesday to Friday, ending near the week’s low of $0.6001. Weekly amplitude was 209.76%, and average daily volume of about 6.64m shares was far above the 81k median. Turnover was extremely heavy.
Key Events
The main company-specific development was the national in-network agreement with Aetna for CNSide tests, announced on Wednesday. That was the only substantive business item among this week’s news, with the rest of the headlines dominated by intraday alerts showing the stock hitting record lows on multiple sessions. After a short-lived 17% intraday gain on Tuesday, Cerenome tumbled over 16%, 13%, and 10% on Wednesday, Thursday, and Friday respectively. The week’s story is one of a concrete commercial agreement sitting alongside a continuing sell-off in the share price.
Analyst Ratings
Four brokers cover the stock: three rate it buy and one rates it overweight, with no hold, underweight, or sell ratings. The consensus rating is strong buy. The consensus target price of $27.75 sits about 4217.72% above the latest close of $0.6427. Individual targets range from $12 to $43, reflecting wide disagreement. Within the biotechnology industry, Cerenome ranks 329th out of 510 companies by rating position, and the industry average coverage is 8 brokers.
The Week Ahead
On the macro calendar, US wholesale sales are due Monday, with NFIB small business optimism and several CPIs, including core CPI, due Tuesday. On the company side, Cerenome reports fiscal Q3 2026 results after market close on Friday, 13 November. Consensus estimates point to EPS of -$1.03 and revenue of $750k. The Aetna agreement announced this week will be a key focus for any commentary on revenue recognition or forward guidance.
In Short
The week’s tension is between a strong-buy consensus and a target price far above spot on one side, and a stock making record lows on heavy volume on the other. The price-to-book ratio stands at 0.890x, and the latest daily flow snapshot showed net buying from medium and small orders, though the picture is mixed. Next week’s CPI prints will set the broader risk tone, while the earnings report will show whether the Aetna deal translates into a clearer revenue path.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.